<DOC>
	<DOCNO>NCT01672905</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tumor tissue patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This clinical trial study prostate-specific antigen ( PSA ) antibody level sample patient treated prostate cancer trial ECOG-E9802 .</brief_summary>
	<brief_title>PSA Antibody Levels Samples From Patients With Prostate Cancer Treated Protocol ECOG-E9802</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate change prostate-specific antigen ( PSA ) antibody level time among patient treat ECOG-E9802 . Secondary - To characterize concordance PSA antibody assessment ECOG Immunology Laboratory NCI Immunology Laboratory . OUTLINE : Previously test sample evaluate change PSA antibody level time ( baseline follow-up 12 24 week ) ECOG Immunology Laboratory NCI Immunology Laboratory . Results compare laboratory .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Samples collect ECOGE9802 ( A Phase II Study PROSTVACV ( Vaccinia ) /TRICOM PROSTVACF ( Fowlpox/TRICOM GMCSF Patients PSA Progression Local Therapy Prostate Cancer ) PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>